This study is testing whether adding a new drug called tazemetostat to a standard two-drug regimen (bendamustine and rituximab) is safe and effective for adults with high-tumor-burden follicular lymphoma who have not had prior treatment. The main goals are to see if the three-dru…
Phase: PHASE1, PHASE2 • Sponsor: Vaishalee Kenkre • Aim: Disease control
Last updated Mar 16, 2026 15:23 UTC